What is Chardan Capital’s Estimate for ANRO FY2025 Earnings?

Alto Neuroscience, Inc. (NYSE:ANRO) – Chardan Capital issued their FY2025 earnings per share estimates for shares of Alto Neuroscience in a research note issued to investors on Tuesday, September 30th. Chardan Capital analyst R. Li expects that the company will earn ($2.45) per share for the year. Chardan Capital has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for Alto Neuroscience’s current full-year earnings is ($2.54) per share. Chardan Capital also issued estimates for Alto Neuroscience’s FY2026 earnings at ($1.80) EPS.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings data on Wednesday, August 13th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.08).

Separately, HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Alto Neuroscience in a report on Monday, August 18th. Five analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $9.80.

Alto Neuroscience Stock Up 9.0%

ANRO opened at $4.44 on Friday. The company has a quick ratio of 18.43, a current ratio of 18.43 and a debt-to-equity ratio of 0.18. Alto Neuroscience has a twelve month low of $1.60 and a twelve month high of $15.04. The company has a market cap of $120.10 million, a PE ratio of -1.86 and a beta of 2.00. The company has a 50-day moving average price of $3.60 and a 200 day moving average price of $2.84.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ANRO. Jane Street Group LLC grew its stake in shares of Alto Neuroscience by 72.0% in the 4th quarter. Jane Street Group LLC now owns 18,600 shares of the company’s stock valued at $79,000 after buying an additional 7,783 shares during the period. AlphaCore Capital LLC increased its stake in Alto Neuroscience by 100.0% during the second quarter. AlphaCore Capital LLC now owns 20,000 shares of the company’s stock worth $44,000 after acquiring an additional 10,000 shares during the last quarter. Bank of Montreal Can acquired a new stake in Alto Neuroscience during the second quarter worth $25,000. Ground Swell Capital LLC purchased a new stake in Alto Neuroscience in the second quarter valued at $27,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new position in shares of Alto Neuroscience in the 2nd quarter valued at $33,000.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.